Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 21.02 CNY -8.49% Market Closed
Market Cap: 8.6B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Shenzhen Chipscreen Biosciences Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Chipscreen Biosciences Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Other Long-Term Assets
ÂĄ26.1m
CAGR 3-Years
-36%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Long-Term Assets
ÂĄ215.7m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
8%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Long-Term Assets
ÂĄ702.3m
CAGR 3-Years
24%
CAGR 5-Years
25%
CAGR 10-Years
33%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Long-Term Assets
ÂĄ928.6m
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Long-Term Assets
ÂĄ84.9m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 909 full-time employees. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
12.22 CNY
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Shenzhen Chipscreen Biosciences Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
26.1m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Other Long-Term Assets amounts to 26.1m CNY.

What is Shenzhen Chipscreen Biosciences Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-5%

Over the last year, the Other Long-Term Assets growth was -49%. The average annual Other Long-Term Assets growth rates for Shenzhen Chipscreen Biosciences Co Ltd have been -36% over the past three years , -5% over the past five years .

Back to Top